Capricor Therapeutics (CAPR) News Today $18.60 -0.86 (-4.42%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Alnylam Pharma (ALNY) Receives a Hold from OppenheimerNovember 1, 2024 | markets.businessinsider.comBrainstorm Cell Therapeutics (BCLI) Receives a Buy from Maxim GroupOctober 31, 2024 | markets.businessinsider.comIterum Therapeutics (ITRM) Receives a Buy from Maxim GroupOctober 30, 2024 | markets.businessinsider.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in OctoberCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 6,180,000 shares, a growth of 17.9% from the September 30th total of 5,240,000 shares. Based on an average daily volume of 2,880,000 shares, the days-to-cover ratio is currently 2.1 days.October 29, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Trading Down 3.3% - Should You Sell?Capricor Therapeutics (NASDAQ:CAPR) Trading Down 3.3% - Should You Sell?October 28, 2024 | marketbeat.comCapricor Therapeutics Options Trading: A Deep Dive into Market SentimentOctober 24, 2024 | benzinga.comPiper Sandler Initiates Coverage of Capricor Therapeutics (CAPR) with Overweight RecommendationOctober 22, 2024 | msn.comCapricor Therapeutics initiated with an Overweight at Piper SandlerOctober 22, 2024 | markets.businessinsider.comBuy Rating for Capricor Therapeutics: Promising Deramiocel Development and Strategic PartnershipsOctober 22, 2024 | markets.businessinsider.comCapricor Therapeutics files to sell 2.8M shares of common stock for holdersOctober 22, 2024 | msn.comCapricor Therapeutics (NASDAQ:CAPR) Trading Up 4.3% - Here's WhyCapricor Therapeutics (NASDAQ:CAPR) Shares Up 4.3% - What's Next?October 21, 2024 | marketbeat.comCapricor Therapeutics initiated at Overweight by Piper SandlerOctober 21, 2024 | msn.comPiper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR)Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday. They issued an "overweight" rating and a $35.00 price target on the stock.October 21, 2024 | marketbeat.comCapricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesOctober 20, 2024 | finance.yahoo.comCapricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesOctober 18, 2024 | globenewswire.comCapricor Therapeutics IncOctober 18, 2024 | money.usnews.comWhy Capricor Therapeutics (CAPR) Shares Are Trading LowerOctober 17, 2024 | benzinga.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Down - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down - Time to Sell?October 17, 2024 | marketbeat.comCapricor Therapeutics Shares Slip Premarket on Stock OfferingOctober 17, 2024 | marketwatch.comCapricor Therapeutics Prices Public Offering Of 4.412 Million Shares At $17/shr; Stock DownOctober 17, 2024 | markets.businessinsider.comCapricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common StockOctober 17, 2024 | globenewswire.comCapricor Therapeutics Announces Proposed Public Offering of Common StockOctober 16, 2024 | globenewswire.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Down 2.5% - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.5% - Here's WhyOctober 16, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Shares Up 0.8% - Time to Buy?Capricor Therapeutics (NASDAQ:CAPR) Trading 0.8% Higher - What's Next?October 15, 2024 | marketbeat.comCapricor touts long-term efficacy of DMD therapy ahead of FDA applicationOctober 15, 2024 | finance.yahoo.comCapricor Therapeutics (CAPR) Receives a Buy from OppenheimerOctober 15, 2024 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Shares Up 5.2% - What's Next?Capricor Therapeutics (NASDAQ:CAPR) Trading 5.2% Higher - What's Next?October 14, 2024 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Decline in Short InterestCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 5,240,000 shares, a decrease of 30.4% from the September 15th total of 7,530,000 shares. Based on an average daily trading volume, of 2,450,000 shares, the days-to-cover ratio is presently 2.1 days.October 12, 2024 | marketbeat.com$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 TodayOctober 12, 2024 | benzinga.comCapricor Announces Long-Term Data From HOPE-2 OLE Study Of Deramiocel For DMD Treatment; Stock UpOctober 12, 2024 | markets.businessinsider.comCapricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 YearsOctober 12, 2024 | finance.yahoo.comCapricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of "Buy" from AnalystsShares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have earned a consensus recommendation of "Buy" from the five research firms that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12 month price objective amoOctober 12, 2024 | marketbeat.comCapricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society CongressOctober 11, 2024 | globenewswire.com89,314 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Acquired by Marshall Wace LLPMarshall Wace LLP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 89,314 shares of the biotechnology company's stock, valued at approxOctober 11, 2024 | marketbeat.comCapricor Therapeutics Inc (CAPR) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...October 10, 2024 | finance.yahoo.comBuy Rating Affirmed for Capricor Therapeutics Amid Promising Developments in DMD-cardiomyopathy TreatmentOctober 10, 2024 | markets.businessinsider.comCapricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyOctober 9, 2024 | globenewswire.comRenaissance Technologies LLC Acquires 84,350 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)Renaissance Technologies LLC boosted its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 158.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 137,500 shares of the biotechnoloOctober 9, 2024 | marketbeat.comOppenheimer Keeps Their Buy Rating on Capricor Therapeutics (CAPR)October 8, 2024 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading Volume - Here's What HappenedCapricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading Volume - Still a Buy?October 7, 2024 | marketbeat.comMarketBeat Week in Review – 9/30 - 10/4 (CAPR)A strong jobs report and a temporary settlement of the port strike lifted stocks but inflation and earnings data could set investors up for more volatilityOctober 5, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Should You Buy?Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Here's WhyOctober 4, 2024 | marketbeat.comCapricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society CongressOctober 4, 2024 | globenewswire.comCapricor Therapeutics (NASDAQ:CAPR) Trading Up 4.1%Capricor Therapeutics (NASDAQ:CAPR) Trading 4.1% HigherOctober 3, 2024 | marketbeat.comIs Capricor Therapeutics, Inc. (CAPR) the Best Russell 2000 Stock to Buy According to Analysts?October 3, 2024 | msn.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Down to $15.01Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down to $15.01October 2, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Hits New 1-Year High at $17.61Capricor Therapeutics (NASDAQ:CAPR) Hits New 1-Year High at $17.61October 1, 2024 | marketbeat.comStock Traders Purchase High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR)Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 13,044 call options on the stock. This represents an increase of approximately 748% compared to the average volume of 1,538 call options.October 1, 2024 | marketbeat.comHere's How Much $100 Invested In Capricor Therapeutics 5 Years Ago Would Be Worth TodaySeptember 30, 2024 | benzinga.comCapricor Therapeutics Is Up Over 100%, Could Rise Even HigherCapricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathySeptember 30, 2024 | marketbeat.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Countdown to the biggest trade of my 25 yr career (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025. Click here to see the surprising reason why CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.210.46▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼43▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LPTX News Today CLSD News Today PRPH News Today EYEN News Today NRBO News Today TNXP News Today GLMD News Today TGTX News Today PBH News Today PRGO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPR Stock Alerts